Mounjaro (tirzepatide) is a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus in adults
Another observational trial published in September 2024 found that semaglutide was associated with reduced opioid overdose risk in patients with comorbid type 2 diabetes and opioid use disorder, and a study published in July last year also found that semaglutide was associated with a lower risk of regular tobacco use in patients with type 2 diabetes who were tobacco smokers, with semaglutide-treated patients seeking fewer healthcare resources to treat their tobacco addiction
Induction Acetic acid was used to induce UC, replicating acute inflammatory conditions (34, 35)
Written by Jordan Weiss and reviewed by Daniel Angerbauer, DO, and republished with permission from Atria Health and Research Institute
Additional Research Notes Improper storage, reconstitution, or handling practices may increase the likelihood of: Injection-site irritation Local sensitivity reactions Reduced peptide stability or consistency Response variability between research protocols Responses and tolerability observations may vary depending on: Dosage range Administration frequency Protocol duration Skin type and physiological status Overall individual sensitivity For Research Use Only Not intended to diagnose, treat, cure, or prevent any disease
